332073-48-0

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3,3-(PROPYLENEDIOXO)-1,3-DIHYDRO-INDOLE-2-ONE is used as a pharmaceutical compound for its antiviral and antitumor activities. Its unique structure and properties make it a promising candidate for the development of new drugs to treat various diseases.
Used in Medicinal Chemistry Research:
5-BROMO-3,3-(PROPYLENEDIOXO)-1,3-DIHYDRO-INDOLE-2-ONE is used as a building block in the synthesis of various biologically active molecules. Researchers in the field of medicinal chemistry utilize 5-BROMO-3,3-(PROPYLENEDIOXO)-1,3-DIHYDRO-INDOLE-2-ONE to create new molecules with potential therapeutic applications.
Used in Drug Development:
5-BROMO-3,3-(PROPYLENEDIOXO)-1,3-DIHYDRO-INDOLE-2-ONE is used in drug development to explore its potential as a lead compound for the creation of new pharmaceuticals. Its unique properties and pharmacological activities make it an interesting target for further research and development.

Upstream product

• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 504-63-2 trimethyleneglycol 
• 66475-83-0 N-(4-bromophenyl)-2-(hydroxyimino) acetamide 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 1163260-19-2 N-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)-5-bromo-3,3-(trimethylenedioxy)indolin-2-one 
• 10378-06-0 2-methyl-(3,4,6-tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoso)[1,2-d]-2-oxazoline 

Relevant academic research and scientific papers

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups

As a hot topic of epigenetic studies, histone deacetylases (HDACs) are related to lots of diseases, especially cancer. Further researches indicated that different HDAC isoforms played various roles in a wide range of tumor types. Herein a novel series of HDAC inhibitors with isatin-based caps and o-phenylenediamine-based zinc binding groups have been designed and synthesized through scaffold hopping strategy. Among these compounds, the most potent compound 9n exhibited similar if not better HDAC inhibition and antiproliferative activities against multiple tumor cell lines compared with the positive control entinostat (MS-275). Additionally, compared with MS-275 (IC50 values for HDAC1, 2 and 3 were 0.163, 0.396 and 0.605?μM, respectively), compound 9n with IC50 values of 0.032, 0.256 and 0.311?μM for HDAC1, 2 and 3 respectively, showed a moderate HDAC1 selectivity.

Design, synthesis and preliminary biological evaluation of indoline-2,3-dione derivatives as novel HDAC inhibitors

Histone deacetylases (HDACs) are zinc-dependent or NAD+ dependent enzymes and play a critical role in the process of tumor development. Herein a series of indoline-2,3-dione derivatives have been designed and synthesized as potential HDACs inhibitors. The preliminary biological evaluation showed that most compounds synthesized have exhibited moderate Hela cell nuclear extract inhibitory activities, among which compound 25a (IC50 = 10.13 nM) has shown the best efficacy. The anti-proliferative activities of some of these compounds were also discussed.

Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN)

Aminopeptidase N (APN/CD13), as a zinc-containing ectoenzyme, plays a critical role in the process of tumor angiogenesis, invasion and metastasis. Through the docking-based virtual screening of chemical databases and the further activity assay, we discovered that compound 10c exhibits potent and selective inhibitory ability towards APN. In addition, a series of indoline-2,3-dione derivates have been designed and synthesized as APN inhibitors. The results of preliminary activity evaluation showed that compound 12a (IC50 = 0.074 ± 0.0026 μM) exhibited the best inhibitory activity against APN, which could be used for further anticancer agent research.

3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as potent non-peptidic inhibitors of caspase-3

Cysteine-dependant aspartyl protease (caspase) activation has been implicated as a part of the signal transduction pathway leading to apoptosis. It has been postulated that caspase-3 inhibition could attenuate cell damage after an ischemic event and thereby providing for a novel neuroprotective treatment for stroke. As part of a program to develop a small molecule inhibitor of caspase-3, a novel series of 3,4-dihydropyrimido(1,2-a)indol-10(2H)-ones (pyrimidoindolones) was identified. The synthesis, biological evaluation and structure-activity relationships of the pyrimidoindolones are described.

Pyrimidoindolones and methods for using same

Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.